Health chiefs are being urged to reconsider approving breakthrough Alzheimer's drugs, lecanemab and donanemab, for use on the NHS. The drugs have been shown to slow the progression of the disease by up to 35% in its early stages. The National Institute for Health and Care Excellence (NICE) will convene a third committee meeting in May to evaluate the drugs' effectiveness. The provisional decision to block the drugs last year was met with criticism from campaigners and charities. If approved, an estimated 70,000 adults in England could be eligible for the treatment.